The landscape of hereditary angioedema (HAE) treatment witnessed transformative developments throughout 2024, with breakthrough therapies and strategic pharmaceutical partnerships reshaping patient care options.
Gene Editing Breakthrough Shows Promising Results
In a landmark development, Intellia Therapeutics' gene-editing therapy NTLA-2002 demonstrated exceptional efficacy in Phase 1 clinical trials, achieving a 95% reduction in monthly HAE attacks among 10 participants. The therapy's success in sustainably reducing kallikrein enzyme levels led to the initiation of the Phase 3 HAELO trial, marking a significant step toward potential regulatory approval.
Multiple Therapeutic Candidates Advance Through Clinical Pipeline
The year saw substantial progress in several HAE treatments. Ionis Pharmaceuticals' donidalorsen reached a crucial milestone with its FDA application submission, based on positive Phase 3 OASIS-HAE trial results. A decision is anticipated by August 21, 2025. Meanwhile, CSL Behring's garadacimab demonstrated promising long-term safety profiles in Phase 3 extension studies, with both U.S. and European regulatory authorities currently reviewing the therapy.
Established Treatments Prove Efficacy in New Populations
Takeda's Takhzyro (lanadelumab) reinforced its therapeutic value with new data showing a 94.7% reduction in monthly attacks among adolescent patients aged 12-17 years. The HELP open-label extension study revealed that nearly all participants achieved attack-free days, with eight patients experiencing complete attack prevention during treatment.
Strategic Industry Partnerships and Commercial Developments
Significant business developments included Otsuka Pharmaceutical's acquisition of exclusive rights to commercialize donidalorsen in Europe and the Asia-Pacific region. Additionally, Takeda partnered with Pentavere Research Group to establish one of the largest datasets for ultra-rare HAE variants, aiming to address critical knowledge gaps and improve treatment strategies.
Real-World Evidence Supports Preventive Treatments
Long-term preventive treatments continued to demonstrate effectiveness in real-world settings. Haegarda showed an 80.2% reduction in annualized attack frequency among 36 adults previously using on-demand therapy, while BioCryst's Orladeyo (berotralstat) achieved an 84.8% reduction in monthly attacks over approximately two years of treatment in Japanese patients.
Emerging Treatment Options
Pharvaris advanced its development of deucrictibant, with the FDA lifting its clinical hold on preventive treatment trials and the initiation of the Phase 3 RAPIDe-3 study for on-demand therapy. This development provides hope for additional treatment options for HAE patients in the future.
These advances collectively represent significant progress in addressing the unmet needs of HAE patients, offering new hope through innovative therapeutic approaches and improved treatment options.
